# US 11,026,963 B2 · Senolytic compositions and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,963 B2 - Document ID: US11026963B2 - Status: Granted - Kind: B2 - Application number: 16/508,477 - Filed: 2019-07-11 - Published: 2020-01-16 - Granted: 2021-06-08 - Earliest claimed: 2018-07-11 - Assignees: Rubedo Life Sciences, Inc. - Applicants: Rubedo Life Sciences, Inc. - Inventors: Mark A. Gallop; Julian Klein; Marco Quarta - Web page: https://patentgrep.com/patent/US11026963B2 ## CPC - A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom - A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine - A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages - A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom - A61K 31/7064: containing condensed or non-condensed pyrimidines - A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids} - A61P 35/04: specific for metastasis - C07H 5/04: to nitrogen - C07H 15/18: Acyclic radicals, substituted by carbocyclic rings - C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings - C07H 99/00: Subject matter not provided for in other groups of this subclass - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13) ## Abstract Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases. ## Claims ### Claim 1 A compound having the structure: or pharmaceutically acceptable salts, hydrates or solvates thereof. ### Claim 2 (depends on 1) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient. ### Claim 3 A compound having the structure: or pharmaceutically acceptable salts, hydrates or solvates thereof. ### Claim 4 (depends on 3) A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable excipient. ### Claim 5 A compound having the structure: or pharmaceutically acceptable salts, hydrates or solvates thereof. ### Claim 6 (depends on 5) A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable excipient. ### Claim 7 A compound having the structure: or pharmaceutically acceptable salts, hydrates or solvates thereof. ### Claim 8 (depends on 7) A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable excipient. ### Claim 9 (depends on 1) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of claim 1. ### Claim 10 (depends on 2) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the pharmaceutical composition of claim 2. ### Claim 11 (depends on 3) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of claim 3. ### Claim 12 (depends on 4) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the pharmaceutical composition of claim 4. ### Claim 13 (depends on 5) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of claim 5. ### Claim 14 (depends on 6) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the pharmaceutical composition of claim 6. ### Claim 15 (depends on 7) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of claim 7. ### Claim 16 (depends on 8) A method for treating a senescence-associated disease or disorder comprising administering to a subject in need thereof a therapeutically-effective amount of a pharmaceutical composition of claim 8.